title: Ruthenium-106 brachytherapy.
abstract: Brachytherapy is the most common method for treating uveal melanoma, and currently the ruthenium-106 (Ru-106) and iodine-125 (I-125) applicators are the most frequently used. Ru-106 applicators were introduced by Prof. Peter Lommatzsch in the 1960s, and since then have been used widely by many ocular oncologists, mainly in Europe. The Ru-106 isotope is a beta ray (electron) emitter, and as such it has a limited depth of penetration. This is the reason why many experts use Ru-106 applicators for tumors with a maximal thickness of up to 7.0 mm, although others use it successfully for thicker tumors. The Ru-106 applicators are manufactured commercially and have a half-life of about 1 year. Ru-106 brachytherapy for uveal melanoma provides excellent local control rates and eye preservation with a relatively low recurrence rate. The main advantage of Ru-106 over other isotopes is the better preservation of vision in the treated eye, and less damage to the healthy parts of the eye due to its limited range of radiation. This can also be achieved by positioning the Ru-106 plaque eccentrically, away from the macula and optic nerve head. Ru-106 brachytherapy can be used in combination with other methods of treatment of uveal melanoma, such as local resection or transpupillary thermotherapy, and is sporadically combined with other isotopes, such as gamma-emitting cobalt-60 and I-125.
authors: Department of Ophthalmology, Jonas Friedenwald Professor of Ophthalmic Research, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
authors: Jacob
authors: J
authors: Pe'er
mesh_terms: D001918:Brachytherapy / Q000379:methods*; D006801:Humans; D008545:Melanoma / Q000532:radiotherapy*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D012429:Ruthenium Radioisotopes / Q000627:therapeutic use*; D016896:Treatment Outcome; D014604:Uveal Neoplasms / Q000532:radiotherapy*; D000098943:Uveal Melanoma
chemical_list: D012429:Ruthenium Radioisotopes